Skip to content

QURE

uniQure N.V.

NASDAQ · NLHealthcareBiotechnology
$39.70-1.37%

Price as of Jul 20, 2026

QURE growth

uniQure N.V. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
-10.4%
EBITDA
+6.4%
EBIT
-12.9%
EPS
+20.0%
Free cash flow
+2.1%
Operating cash flow
-3.5%

Forward estimates

Revenue
+179.5%
EBITDA
+73.4%
EPS
-96.4%

Three-year CAGR

Revenue
-46.7%
EBITDA
+27.5%
EBIT
-1.9%
Net income
+16.9%
EPS
+29.7%
Free cash flow
+4.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.